1699-39-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(3-Benzyloxy-4-methoxy-phenyl)-acetonitrile is used as a synthetic intermediate for the development of pharmaceutical compounds. Its presence on the phenyl ring and the presence of benzyloxy and acetonitrile groups may allow for reactivity with acids or bases, and participation in various types of organic reactions, which can be harnessed in the synthesis of drug molecules.
Used in Polymer Synthesis:
(3-Benzyloxy-4-methoxy-phenyl)-acetonitrile is used as a building block in the synthesis of polymers. (3-BENZYLOXY-4-METHOXY-PHENYL)-ACETONITRILE's structure may contribute to the formation of polymers with specific properties, such as improved stability or reactivity, depending on the desired application.

InChI:InChI=1/C16H15NO2/c1-18-15-8-7-13(9-10-17)11-16(15)19-12-14-5-3-2-4-6-14/h2-8,11H,9,12H2,1H3

Upstream product

• 1699-38-3 3-benzyloxy-4-methoxy-benzyl chloride 
• 142-84-7 di-n-propylamine 
• 13435-20-6 tetraethylammoniumcyanide 
• 1860-60-2 3-benzyloxy-4-methoxy-benzyl alcohol 
• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 100-39-0 benzyl bromide 
• 143-33-9 sodium cyanide 
• 38836-54-3 3-benzyloxy-4-methoxyphenylpyruvic acid oxime 
• 151-50-8 potassium cyanide 
• 773837-37-9 sodium cyanide 
• 55667-12-4 4-methoxy-3-(benzyloxy)benzyl bromide 
• 621-59-0 isovanillin 

Downstream Products

• 70413-06-8 2,3',4,6-tetrahydroxy-4'-methoxy-desoxybenzoin 
• 64640-60-4 2,4-dihydroxy-3,6-dimethoxyphenyl-3-hydroxy-4-methoxybenzyl ketone 
• 4468-58-0 3-hydroxy-4-methoxyphenylacetonitrile 
• 763109-95-1 1-(3-benzyloxy-4-methoxyphenyl)cyclopen-3-ene-1-carbonitrile 
• 401519-01-5 ethyl {4-[3-(benzyloxy)-4-methoxyphenyl]-4-cyanopiperidin-1-yl}acetate 
• 401519-05-9 ethyl {4-cyano-4-[3-(2,3-dihydro-1H-inden-2-yloxy)-4-methoxyphenyl]piperidin-1-yl}acetate 
• 73357-19-4 (5-hydroxy-4-methoxy-2-nitro-phenyl)-acetic acid 
• 195140-75-1 3-(3-benzyloxy-4-methoxy-phenyl)-propane-1,2-diol 
• 854668-31-8 1-(3-benzyloxy-4-methoxy-phenyl)-3-diazo-acetone 
• 78792-73-1 5-benzyloxy-4-methoxy-2-nitrophenylacetic acid 
• 854668-30-7 1-acetoxy-3-(3-benzyloxy-4-methoxy-phenyl)-acetone 
• 13255-24-8 (3-benzyloxy-4-methoxy-phenyl)-acetic acid-(3,4-bis-benzyloxy-phenethylamide) 
• 80943-16-4 1-(3-hydroxy-4-methoxy-benzyl)-7-methoxy-3,4-dihydro-isoquinolin-6-ol 

Relevant academic research and scientific papers

PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID HAVING A HYDROXYL GROUP ON THE PHENANTHRENE RING THEREOF, PREPARATION METHOD AND USE THEREOF

A phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof was synthesized, which exhibits potent activity as an anticancer agent against, such as breast cancer, lung cancer, and prostate cancer.

Designing new analogs for streamlining the structure of cytotoxic lamellarin natural products

Despite the therapeutic potential of marine-derived lamellarin natural products, their preclinical development has been hampered by their lipophilic nature, causing very poor aqueous solubility. In order to develop more drug-like analogs, their structure was streamlined in this study from both the cytotoxic activity and lipophilicity standpoints. First, a modified total synthetic route was successfully devised to construct a library of 59 systematically designed lamellarin analogs, which were then subjected to cytotoxicity and log P determinations. Along with the 25 first-generation lamellarins previously synthesized in our laboratory, the structure-activity and structure-lipophilicity relationships were extensively evaluated. Our results clearly indicated the additional structural requirements around the lamellarin skeleton which, when combined with those reported previously, can provide invaluable guidance for further modifications to increase the aqueous solubility of these compounds.

Facile and Divergent Synthesis of Lamellarins and Lactam-Containing Derivatives with Improved Drug Likeness and Biological Activities

With the goal to improve the aqueous solubility of lamellarins, the lactone ring in their skeleton was replaced with a lactam moiety in azalamellarins. However, the reported synthetic route produced such derivatives in very low yields. Hence, this study focused on developing an efficient simplified total synthetic scheme that could furnish both azalamellarins and the parent lamellarins from the same pyrrole ester intermediates. Subsequent comparative profiling revealed that the introduced lactone-to-lactam replacement rendered these molecules less lipophilic, whereas their cancer cytotoxicity remained equipotent to that of the parent compounds. Interestingly, their inhibitory activity was significantly enhanced towards the multifaceted GSK-3β enzyme. Our results clearly demonstrate the therapeutic potential of this promising class of marine-derived natural products and justify their further development, especially into anticancer agents.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Repurposing human PDE4 inhibitors for neglected tropical diseases: Design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors

A medicinal chemistry exploration of the human phosphodiesterase 4 (hPDE4) inhibitor cilomilast (1) was undertaken in order to identify inhibitors of phosphodiesterase B1 of Trypanosoma brucei (TbrPDEB1). T. brucei is the parasite which causes African sleeping sickness, a neglected tropical disease that affects thousands each year, and TbrPDEB1 has been shown to be an essential target of therapeutic relevance. Noting that 1 is a weak inhibitor of TbrPDEB1, we report the design and synthesis of analogs of this compound, culminating in 12b, a sub-micromolar inhibitor of TbrPDEB1 that shows modest inhibition of T. brucei proliferation.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Design, synthesis and antiproliferative activity of tripentones: A new series of antitubulin agents

Structure-activity relationship studies of a new series of tripentones (thieno[2,3-b]pyrrolizin-8-ones), led us to prepare several derivatives with antiproliferative activities. The most promising 3-(3-hydroxy-4-methoxyphenyl)thieno[2,3-b]pyrrolizin-8-one 20 (leukemia L1210, IC50 = 15 nM) was shown to be a potent inhibitor of tubulin polymerization.

Vanilloid and isovanilloid analogues as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases

As aminoacyl adenylate surrogates, a series of methionyl and isoleucyl phenolic analogues containing bioisosteric linkers mimicking ribose have been investigated. Inhibition of synthesized compounds to the aminoacylation reaction by the corresponding Escherichia coli methionyl-tRNA and isoleucyl-tRNA synthetases indicated that 18 was found to be a potent inhibitor of isoleucyl-tRNA synthetase. A molecular modeling study demonstrated that in 18, isovanillate and hydroxamate served as proper surrogates for adenine and ribose in isoleucyl adenylate, respectively.

8H-thieno-[2,3-b]pyrrolizin-8-one compounds

A compound selected from those of formula (I): STR1 wherein: R1 represents hydrogen, halogen, alkyl, nitro, hydroxy, alkoxy, trihaloalkyl, trihaloalkoxy or optionally substituted amino, R2 represents optionally substituted aryl or heteroaryl, R3 represents hydrogen, halogen, alkyl, nitro, hydroxy, alkoxy, trihaloalkyl, trihaloalkoxy or optionally substituted amino, their isomers and addition pharmaceutically-acceptable acid or base salts thereof and medicinal products containing the same are useful in the treatment of cancer.